JP2013512195A - ビタミンｄ耐性腫瘍細胞においてビタミンｄ感受性を回復させるための免疫調節性化合物 - Google Patents

ビタミンｄ耐性腫瘍細胞においてビタミンｄ感受性を回復させるための免疫調節性化合物 Download PDF

Info

Publication number
JP2013512195A
JP2013512195A JP2012540169A JP2012540169A JP2013512195A JP 2013512195 A JP2013512195 A JP 2013512195A JP 2012540169 A JP2012540169 A JP 2012540169A JP 2012540169 A JP2012540169 A JP 2012540169A JP 2013512195 A JP2013512195 A JP 2013512195A
Authority
JP
Japan
Prior art keywords
vitamin
alkyl
cells
agent
immunomodulatory compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012540169A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013512195A5 (https=
Inventor
キャロル ブロッソー，
ジャスティン ブレイク バルトレット，
アンガス ジョージ ダルグリッシュ，
ケイ ウィニフレッド コルストン，
クリスティン ガルスティアン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2013512195A publication Critical patent/JP2013512195A/ja
Publication of JP2013512195A5 publication Critical patent/JP2013512195A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012540169A 2009-11-24 2010-11-24 ビタミンｄ耐性腫瘍細胞においてビタミンｄ感受性を回復させるための免疫調節性化合物 Withdrawn JP2013512195A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26406209P 2009-11-24 2009-11-24
US61/264,062 2009-11-24
US32447310P 2010-04-15 2010-04-15
US61/324,473 2010-04-15
PCT/US2010/057951 WO2011066351A1 (en) 2009-11-24 2010-11-24 Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015101583A Division JP5839637B2 (ja) 2009-11-24 2015-05-19 ビタミンｄ耐性腫瘍細胞においてビタミンｄ感受性を回復させるための免疫調節性化合物

Publications (2)

Publication Number Publication Date
JP2013512195A true JP2013512195A (ja) 2013-04-11
JP2013512195A5 JP2013512195A5 (https=) 2013-12-12

Family

ID=44066895

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012540169A Withdrawn JP2013512195A (ja) 2009-11-24 2010-11-24 ビタミンｄ耐性腫瘍細胞においてビタミンｄ感受性を回復させるための免疫調節性化合物
JP2015101583A Expired - Fee Related JP5839637B2 (ja) 2009-11-24 2015-05-19 ビタミンｄ耐性腫瘍細胞においてビタミンｄ感受性を回復させるための免疫調節性化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015101583A Expired - Fee Related JP5839637B2 (ja) 2009-11-24 2015-05-19 ビタミンｄ耐性腫瘍細胞においてビタミンｄ感受性を回復させるための免疫調節性化合物

Country Status (6)

Country Link
US (2) US8841325B2 (https=)
EP (1) EP2504703B1 (https=)
JP (2) JP2013512195A (https=)
CA (1) CA2780998C (https=)
MX (1) MX2012005849A (https=)
WO (1) WO2011066351A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533955A (ja) * 2014-10-30 2017-11-16 カンプー バイオファーマシューティカルズ リミテッド イソインドリン誘導体、その中間体、製造方法、薬物組成物及び応用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
WO2011066351A1 (en) * 2009-11-24 2011-06-03 Celgene Corporation Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060030594A1 (en) * 2002-05-17 2006-02-09 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US20080286232A1 (en) * 2002-05-17 2008-11-20 Celgene Corporation Methods for treating sarcoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6 dioxo(3-piperidyl))-isoindoline-1,3-dione

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
CN102342938B (zh) * 2002-05-17 2014-08-20 细胞基因公司 用于治疗和控制实体瘤的方法及组合物
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
WO2005016872A1 (en) 2003-06-11 2005-02-24 Novacea, Inc. Treatment of lung cancer with active vitamin d compounds in combination with other treatments
US20060078494A1 (en) * 2004-09-24 2006-04-13 Sapphire Therapeutics, Inc. Use of inhibitors of 24-hydroxylase in the treatment of cancer
PL2068874T3 (pl) * 2006-08-07 2015-06-30 Abbvie Biotherapeutics Inc Sposoby leczenia szpiczaka mnogiego z użyciem terapii skojarzonych opartych na przeciwciałach anty-cs1
RU2536242C2 (ru) * 2007-09-28 2014-12-20 Антродженезис Корпорейшн Угнетение опухолей с помощью плацентарного перфузата человека и выделенных из плаценты человека вспомогательных натуральных клеток-киллеров
WO2010104588A2 (en) * 2009-03-10 2010-09-16 The Johns Hopkins University Compositions and methods for characterizing and treating neoplasia
WO2011066351A1 (en) * 2009-11-24 2011-06-03 Celgene Corporation Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060030594A1 (en) * 2002-05-17 2006-02-09 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US20080286232A1 (en) * 2002-05-17 2008-11-20 Celgene Corporation Methods for treating sarcoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6 dioxo(3-piperidyl))-isoindoline-1,3-dione

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6014044703; ｔｈｅ　ｐｈａｒｍａｌｅｔｔｅｒ，　２００１，　"Ｃｅｌｇｅｎｅ　ｄｒｕｇ　ｐｒｏｍｉｓｅｓ　ａｃｔｉｖｉｔｙ　ｉｎ　ｓｏｌｉｄ　ｔｕｍｏｒｓ．" *
JPN6014044705; Ｌａｎｃｅｔ，　１９８９，　Ｖｏｌ．３３３　Ｉｓｓ．８６３１，　ｐ．１８８-１９１ *
JPN6014044707; Ｃａｎｃｅｒ　Ｒｅｓ．，　１９９４，　Ｖｏｌ．５４　Ｎｏ．２１　ｐ．５７１１-５７１７ *
JPN6014044709; Ａｐｏｐｔｏｓｉｓ，　２０１２，　Ｖｏｌ．１７　Ｎｏ．２，　ｐ．１６４-１７３ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533955A (ja) * 2014-10-30 2017-11-16 カンプー バイオファーマシューティカルズ リミテッド イソインドリン誘導体、その中間体、製造方法、薬物組成物及び応用

Also Published As

Publication number Publication date
EP2504703A4 (en) 2013-05-08
JP2015145432A (ja) 2015-08-13
EP2504703B1 (en) 2016-11-16
EP2504703A1 (en) 2012-10-03
CA2780998A1 (en) 2011-06-03
US8841325B2 (en) 2014-09-23
WO2011066351A1 (en) 2011-06-03
US20150283124A1 (en) 2015-10-08
US20130171196A1 (en) 2013-07-04
CA2780998C (en) 2016-07-12
JP5839637B2 (ja) 2016-01-06
MX2012005849A (es) 2012-08-23

Similar Documents

Publication Publication Date Title
JP4754967B2 (ja) １−オキソ−２−（２，６−ジオキソピペリジン−３−イル）−４−メチルイソインドリンを含む脳腫瘍の治療及び管理のための医薬組成物
JP6194335B2 (ja) 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物
US7323479B2 (en) Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
JP5465005B2 (ja) マントル細胞リンパ腫治療のための３−（４−アミノ−１−オキソ−１，３−ジヒドロ−イソインドール−２−イル）−ピペリジン−２，６−ジオンの使用
US20050100529A1 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
JP2017222686A (ja) 特定の白血病の治療のために３−（４−アミノ−１−オキソ−１，３−ジヒドロ−イソインドール−２−イル）−ピペリジン−２，６−ジオンを使用する方法
JP2010013482A (ja) 癌および他の疾患を治療および管理するための選択的サイトカイン阻害薬を用いた方法および組成物
JP5839637B2 (ja) ビタミンｄ耐性腫瘍細胞においてビタミンｄ感受性を回復させるための免疫調節性化合物
ZA200509232B (en) Methods for treating cancers using polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
AU2016203022A1 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150519

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150610

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20150612